mTor Inhibitors for the Treatment of Endometriosis

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2018; 78(03): 283-284
DOI: 10.1055/s-0043-124518

GebFra Science

Letter to the Editor

Georg Thieme Verlag KG Stuttgart · New York

mTOR-Inhibitoren zur Behandlung von Endometriose

Fabio Barra

¹Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Genoa, Italy

²Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

,

Simone Ferrero

¹Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Genoa, Italy

²Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

References
1 Kacan T, Yildiz C, Baloglu Kacan S. et al. Everolimus as an mTOR inhibitor suppresses endometriotic implants: an experimental rat study. Geburtsh Frauenheilk 2017; 77: 66-72
2 Keenan JA, Williams-Boyce PK, Massey PJ. et al. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 1999; 72: 135-141
3 Oral E, Demir B, Inceboz U. Endometriosis and ovarian reserve. Womens Health (Lond) 2015; 11: 671-675
4 Cinar O, Seval Y, Uz YH. et al. Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online 2009; 19: 864-871
5 Leconte M, Nicco C, Ngo C. et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011; 179: 880-889
6 Wesolowski R, Abdel-Rasoul M, Lustberg M. et al. Treatment-related mortality with everolimus in cancer patients. Oncologist 2014; 19: 661-668
7 Gajate P, Alonso-Gordoa T, Martinez-Saez O. et al. Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms. Clin Transl Oncol 2017;
8 Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 2013; 12: 177-186